CPY3A4-mediated α-hydroxyaldehyde formation in saquinavir metabolisms

Drug Metabolism and Disposition

Volumn 42, Issue 2, 2014, Pages 213-220

  Li, Feng ^a   Lu, Jie ^b   Ma, Xiaochao ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYALDEHYDE; CYTOCHROME P450 3A4; DRUG METABOLITE; N TERT BUTYLDECAHYDRO ISOQUINOLINE 3 CARBOXAMIDE; RECOMBINANT ENZYME; SAQUINAVIR; SEMICARBAZIDE; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG FECES LEVEL; DRUG INTERACTION; DRUG METABOLISM; DRUG URINE LEVEL; LIVER MICROSOME; MALE; METABOLOMICS; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL;

ALDEHYDES; ANIMALS; BIOTRANSFORMATION; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DEALKYLATION; FECES; HIV PROTEASE INHIBITORS; HUMANS; LIVER; MALE; METABOLOMICS; MICE; MICE, KNOCKOUT; RECOMBINANT PROTEINS; SAQUINAVIR;

EID: 84891794649     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.054874     Document Type: Article

References (27)

1. Argikar UA, Gomez J, Ung D, Parkman HP, and Nagar S (2010) Identification of novel metoclopramide metabolites in humans: in vitro and in vivo studies. Drug Metab Dispos 38: 1295-1307.
2. Backman JT, Kivistö KT, Olkkola KT, and Neuvonen PJ (1998) The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 54:53-58. (Pubitemid 28189400)
3. Bailey MJ and Dickinson RG (2003) Acyl glucuronide reactivity in perspective: biological consequences. Chem Biol Interact 145:117-137. (Pubitemid 36398426)
4. Baillie TA (2006) Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem Res Toxicol 19:889-893. (Pubitemid 44092354)
5. Chen C, Meng L, Ma X, Krausz KW, Pommier Y, Idle JR, and Gonzalez FJ (2006) Urinary metabolite profiling reveals CYP1A2-mediated metabolism of NSC686288 (aminoflavone). J Pharmacol Exp Ther 318:1330-1342. (Pubitemid 44268343)
6. Corpechot C, Ping C, Wendum D, Matsuda F, Barbu V, and Poupon R (2006) Identification of a novel 974C - .G nonsense mutation of the MRP2/ABCC2 gene in a patient with Dubin- Johnson syndrome and analysis of the effects of rifampicin and ursodeoxycholic acid on serum bilirubin and bile acids. Am J Gastroenterol 101:2427-2432. (Pubitemid 44477571)
7. Dieckhaus CM, Thompson CD, Roller SG, and Macdonald TL (2002) Mechanisms of idiosyncratic drug reactions: the case of felbamate. Chem Biol Interact 142:99-117. (Pubitemid 35232556)
8. Eagling VA, Back DJ, and Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44: 190-194. (Pubitemid 27327076)
9. Eagling VA, Wiltshire H, Whitcombe IW, and Back DJ (2002) CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica 32:1-17. (Pubitemid 34095130)
10. Fitzsimmons ME and Collins JM (1997) Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 25:256-266. (Pubitemid 27086127)
11. Guengerich FP and MacDonald JS (2007) Applying mechanisms of chemical toxicity to predict drug safety. Chem Res Toxicol 20:344-369. (Pubitemid 46548682)
12. Kapetanovic IM, Torchin CD, Strong JM, Yonekawa WD, Lu C, Li AP, Dieckhaus CM, Santos WL, Macdonald TL, and Sofia RD, et al. (2002) Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro. Chem Biol Interact 142:119-134. (Pubitemid 35238045)
13. Kim AE, Dintaman JM, Waddell DS, and Silverman JA (1998) Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 286:1439-1445. (Pubitemid 29135560)
14. Li F, Lu J, and Ma X (2011a) Metabolomic screening and identification of the bioactivation pathways of ritonavir. Chem Res Toxicol 24:2109-2114.
15. Li F, Lu J, Wang L, and Ma X (2011b) CYP3A-mediated generation of aldehyde and hydrazine in atazanavir metabolism. Drug Metab Dispos 39:394-401.
16. Li F, Wang L, Guo GL, and Ma X (2010) Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice. Drug Metab Dispos 38:871-878.
17. Noble S and Faulds D (1996) Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 52:93-112.
18. O'Brien PJ, Siraki AG, and Shangari N (2005) Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health. Crit Rev Toxicol 35:609-662. (Pubitemid 41693601)
19. Plosker GL and Scott LJ (2003) Saquinavir: a review of its use in boosted regimens for treating HIV infection. Drugs 63:1299-1324. (Pubitemid 36750953)
20. Ribera E, Azuaje C, Lopez RM, Domingo P, Curran A, Feijoo M, Pou L, Sánchez P, Sambeat MA, and Colomer J, et al. (2007) Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. J Antimicrob Chemother 59:690-697. (Pubitemid 47073403)
21. Schmitt C, Riek M, Winters K, Schutz M, and Grange S (2009) Unexpected hepatotoxicity of rifampin and saquinavir/ritonavir in healthy male volunteers. Arch Drug Inf 2:8-16.
22. Spahn-Langguth H and Benet LZ (1992) Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev 24:5-47.
23. Sulkowski MS, Thomas DL, Chaisson RE, and Moore RD (2000) Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283:74-80. (Pubitemid 30038386)
24. Tang W and Lu AY (2010) Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective. Drug Metab Rev 42: 225-249.
25. Tang W, Stearns RA, Wang RW, Miller RR, Chen Q, Ngui J, Bakshi RK, Nargund RP, Dean DC, and Baillie TA (2008) Assessing and minimizing time-dependent inhibition of cytochrome P450 3A in drug discovery: a case study with melanocortin-4 receptor agonists. Xenobiotica 38:1437-1451.
26. Vella S and Floridia M (1998) Saquinavir. Clinical pharmacology and efficacy. Clin Pharmacokinet 34:189-201. (Pubitemid 28112398)
27. Wolf EL, Sprayregen S, Frager D, Rifkin H, and Gliedman ML (1984) Calcification in an insulinoma of the pancreas. Am J Gastroenterol 79:559-561. (Pubitemid 14091516)